mRNA-3705 is Moderna’s second rare disease program to enter clinical studies
mRNA-3705 granted Orphan Drug and Rare Pediatric Disease designation by the U.S. FDA
MMA associated with significant mortality and morbidity; there are no approved therapies
CAMBRIDGE, Mass., August 16, 2021–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the first patient has been enrolled in the Phase…
Source link
